Skip to Main Navigation Skip to Main Content Skip to Footer
search play2 play3 facebook twitter linkedin2 cross
ASCP
  • DASHBOARD
  • STORE
  • LOGOUT
  • STORE
  • LOGIN
Menu
  • My Role
  • Membership
  • Learning
  • Get Involved
  • Careers
  • About ASCP
  • Board of Certification
  • News
  • News
  • News Archive
  • Groups
  • Jobs
  • ASCP
  • News Archive
  • News Detail

M&A Report: Invitae-ArcherDX Merger to Create Precision Oncology Powerhouse

Publication Date: Aug 12, 2020

While M&A deal volume remains abnormally low, business is expected to pick up this summer as the reopening process gets into high gear. Meanwhile, a few new deals are being made, including transactions of major strategic significance.  

Invitae to Merge with ArcherDX

In one of the year’s most significant deals, Invitae announced on June 22 that it plans to acquire fellow cancer genetics firm ArcherDX for $1.4 billion, including $325 million in cash, 30 million shares of Invitae common stock upfront and 27 million more shares later upon the achievement of certain milestones.

The Financing: To finance the deal, Invitae plans to sell $275 million in common stock, $16.85 per share, in a private placement. The firm has also entered into a credit facility of up to $200 million with Perceptive Credit Opportunities Funds.

The Strategy: Already a leader in genetic testing to assess hereditary cancer risk, Invitae will bolster its tumor profiling services and liquid biopsy technology by acquiring ArcherDX’s precision oncology assets, including its Stratafide pan-cancer test for identifying actionable genomic alterations from blood and tissue samples and Personalized Cancer Monitoring platform to assess the progress of cancer treatment and detect early signs of recurrence.

“From the beginning, Invitae's goal has been to aggregate the world's genetic tests into a single platform in service of our mission to bring comprehensive genetic information into mainstream medicine,” noted Invitae CEO Sean George in a statement. In his own statement, ArcherDX CEO Jason Myers said that the firm’s products can help bring precision oncology into regional and community settings, where the majority of cancer patients receive care, and address an estimated $45 billion market opportunity.  

**************

This article and a detailed chart summarizing the Q1 earnings reported by major labs companies originally appeared in G2 Intelligence, Laboratory Industry Report, July 2020

  • My Role
    • Pathologist
    • Resident
    • Lab Professional
    • Program Directors
    • Student
  • Membership
    • Renew Membership
    • Become a Member
    • Get Involved
    • Rewards
    • Member Center
  • Learning
    • Certificate Programs
    • Attend Live Events
    • Explore Books and Journals
    • Quality Improvement Education
    • Access My Education
    • ACCME
    • CC Resources
    • CMP Resources
    • ASCPedia
    • Featured Education
    • Immuno-Oncology
    • ASCP Annual Meeting
    • ASCP Virtual Town Hall Series
    • Inside the Lab
  • Get Involved
    • Get Recognized
    • Receive Awards
    • Serve Your Community
    • Center for Global Health
    • Serve Your Profession
    • Partners in Cancer Diagnosis
    • Institute for Science Technology & Public Policy
    • Choosing Wisely
    • Patient Champions
    • Discover Opportunities
    • Apply to Volunteer
    • Ambassadors
    • ASCP Mentorship Program
  • Careers
    • Find a Job
    • Post a Job
    • Learn About Careers
    • Discover Fellowships
    • Work at ASCP
  • About ASCP
    • Our Mission
    • Supporting Our Members
    • Our Community Efforts
    • ASCP Foundation
    • Contact ASCP
    • Media Relations
  • Board of Certification
    • Get Credentialed
    • Stay Credentialed
    • Verify Credentials
    • Program Directors
    • About BOC
    • Apply Now/Check Status/Update Info
    • Manage Your BOC Account
    • Declaration & Complete CMP
  • News
    • ePolicy News
Chicago (Headquarters)
33 West Monroe Street, Suite 1600, Chicago, IL 60603

Privacy Policy 

Terms of Use

Follow Us

Copyright ©2021 by American Society for Clinical Pathology. All Rights Reserved.